Caris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation

Reuters01-13

Caris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation

Caris Life Sciences Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its leadership in precision oncology, molecular diagnostics, and oncology bioinformatics. The company detailed its expanding offerings in early detection, minimal residual disease (MRD), and monitoring, as well as its technology-enabled platform supporting more than 6,000 oncologists in the U.S. Caris also reported continued growth in its Precision Oncology Alliance (POA), now comprising 99 member sites—including 46 NCI-designated cancer centers—and providing access to a clinico-genomic dataset of over 740,000 patients. The company supports research, publication, and clinical trial efforts across more than 700 locations, with a network of over 4,000 oncologists. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603625529?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 05:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603625529","market":"fut","top_or_hot":-1,"title":"Caris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its leadership in precision oncology, molecular diagnostics, and oncology bioinformatics. The company detailed its expanding offerings in early detection, minimal residual disease (MRD), and monitoring, as well as its technology-enabled platform supporting more than 6,000 oncologists in the U.S. Caris also reported continued growth in its Precision Oncology Alliance (POA), now comprising 99 member sites—including 46 NCI-designated cancer centers—and providing access to a clinico-genomic dataset of over 740,000 patients. The company supports research, publication, and clinical trial efforts across more than 700 locations, with a network of over 4,000 oncologists. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 05:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its leadership in precision oncology, molecular diagnostics, and oncology bioinformatics. The company detailed its expanding offerings in early detection, minimal residual disease (MRD), and monitoring, as well as its technology-enabled platform supporting more than 6,000 oncologists in the U.S. Caris also reported continued growth in its Precision Oncology Alliance (POA), now comprising 99 member sites—including 46 NCI-designated cancer centers—and providing access to a clinico-genomic dataset of over 740,000 patients. The company supports research, publication, and clinical trial efforts across more than 700 locations, with a network of over 4,000 oncologists. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAI","symbol_name":"Caris Life Sciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8JgyHq:1","article_id":"2603625529","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603625529","pubTimestamp":1768254640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Caris Life Sciences Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its leadership in precision oncology, molecular diagnostics, and oncology bioinformatics. The company detailed its expanding offerings in early detection, minimal residual disease , and monitoring, as well as its technology-enabled platform supporting more than 6,000 oncologists in the U.S. Caris also reported continued growth in its Precision Oncology Alliance , now comprising 99 member sites—including 46 NCI-designated cancer centers—and providing access to a clinico-genomic dataset of over 740,000 patients. The company supports research, publication, and clinical trial efforts across more than 700 locations, with a network of over 4,000 oncologists. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAI":"Caris Life Sciences, Inc.","BK4139":"生物科技","BK4104":"贸易公司与经销商"},"translate_title":"Caris Life Sciences在新演示中展示了精准肿瘤学和分子诊断学的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":0.9},"content_text":"Caris Life Sciences Showcases Advances in Precision Oncology and Molecular Diagnostics in New Presentation\n    \n\n        Caris Life Sciences Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its leadership in precision oncology, molecular diagnostics, and oncology bioinformatics. The company detailed its expanding offerings in early detection, minimal residual disease (MRD), and monitoring, as well as its technology-enabled platform supporting more than 6,000 oncologists in the U.S. Caris also reported continued growth in its Precision Oncology Alliance (POA), now comprising 99 member sites—including 46 NCI-designated cancer centers—and providing access to a clinico-genomic dataset of over 740,000 patients. The company supports research, publication, and clinical trial efforts across more than 700 locations, with a network of over 4,000 oncologists. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603625529","isCrawlerRequest":true}